Even FDA's Peter Marks is worried about the commercial viability of gene and cell therapies

Zachary Brennan

Senior Editor

When bluebird bio’s gene therapy to treat beta thalassemia won European approval in 2019, the nearly $2 million per patient price tag for the potential …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Even FDA's Peter Marks is worried about the commercial viability of gene and cell therapies

Zachary Brennan

Senior Editor

Sign up to read this article for free.

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

Pfizer partners with two more Flagship biotechs on obesity, cancer

When generative AI meets the FDA: First digital health adcomm kicks off discussion

Are programs with compounded GLP-1s safe for your population?

Even FDA's Pe­ter Marks is wor­ried about the com­mer­cial vi­a­bil­i­ty of gene and cell ther­a­pies

Zachary Brennan

Senior Editor

Sign up to read this article for free.

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Even FDA's Peter Marks is worried about the commercial viability of gene and cell therapies

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

Pfizer partners with two more Flagship biotechs on obesity, cancer

When generative AI meets the FDA: First digital health adcomm kicks off discussion

Are programs with compounded GLP-1s safe for your population?